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Breast cancer is the most commonly occurring cancer among women. MicroRNAs as noncoding small RNA 
molecules play pivotal roles in cancer-related biological processes. Increased levels of microRNA-29a in the 
serum of breast cancer patients have been reported. Since heat shock proteins (HSPs) play important roles in cell 
events, the quantitative fluctuations in their cellular levels could be deemed as key indicators of how the exerted 
treatment alters cell behavior. In this regard, using an antisense small RNA, we attempted to investigate the effects 
of miR-29a knockdown on the expression of HSPs genes in the MCF-7 breast cancer cell line. MCF-7 cells were 
cultured in high-glucose Dulbecco’s modified Eagle’s medium with 10% FBS. Studied cells were subdivided 
into five groups: treated with scramble, anti-miR-29a, anti-miR-29a + Taxol, Taxol, and control. Taxol was added 
24 h post-anti-miR transfection and RNA extraction, and cDNA synthesis was done 48 h later. The changes in 
expression of HSP27, HSP40, HSP60, HSP70, and HSP90 were evaluated by real-time PCR. Our results revealed 
that inhibitors of microRNA-29a promote apoptosis through upregulation of HSP60 level and downregulation 
of HSP27, HSP40, HSP70, and HSP90 levels and could be contemplated as a compelling alternative for Taxol 
employment with similar effects and/or to sensitize cancer cells to chemotherapy with fewer side effects.
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INTRODUCTION
Breast cancer, usually caused by genetic alterations, 
is one of the most common malignancies among women 
worldwide (1). It is a complex disease characterized by 
heterogeneity of genetic alterations and affected by sev-
eral factors such as age, early menopause, familial his-
tory, and mutations (2). The current treatment for breast 
cancer is a combination of surgery with supplementary 
treatment including anticancer agents, hormonal therapy, 
radiotherapy, and biological treatment (3). It is estimated 
that half of patients with breast cancer will fail to respond 
to initial treatments or will rapidly acquire resistance to 
chemotherapeutic agents (4). As a result, finding new 
therapeutics attracts much attention (5). One of these 
therapeutic targets is microRNAs (miRNAs).
miRNAs are a family of naturally occurring small 
noncoding RNAs, with 18–25 nucleotides in length, that 
regulate gene expression by targeting mRNAs in a sequence 
of specific manner, inducing translational repression or 
mRNA degradation (6–8). miRNAs act as oncogenes or 
tumor suppressors (9). It has an influence on many biologi-
cal processes, including cell proliferation, apoptosis, devel-
opment, differentiation, cell migration, and survival (10). 
There is growing evidence showing the role of miRNAs in 
many human tumors, including ovarian, breast, pancreatic, 
thyroid, and lung cancers.
miRNAs dysregulation in human cancer came from 
molecular studies characterizing the loss of chromosomal 
region 13q14 in human chronic lymphocytic leukemia 
(CLL) (11), which revealed that two miRNAs, mir-15a 
and mir-16-1, were clustered within this chromosomal 
region (12). Following the first finding, miRNA dysregu-
lation has been reported in various cancers. For instance, 
downregulation of miR-143 and miR-145 colon cancer 
70 CHOGHAEI ET AL.
(13,14), let-7 downregulation in lung carcinomas (15), 
and upregulated level of miR-155 in Burkitt’s lymphoma 
has been reported (16).
It has been reported that miR-29a level was sig-
nificantly elevated in breast cancer patient’s sera (17). 
However, the phenomena of miR-29a downregulation 
have been shown to be the case in a broad spectrum of 
other solid tumors, including neuroblastoma, sarcoma, 
and brain tumor (18,19). The miR-29 family consists of 
miR-29a, miR-29b, and miR-29c, reported to be deregu-
lated in various cancers and involved multiple pathways, 
indicating its vital role in tumor genesis, apoptosis, dif-
ferentiation, metastasis, and epigenetic modulation (20). 
miR-29 family is involved in cell apoptosis through 
apoptosis-associated factors such as myeloid cell leuke-
mia (Mcl), B cell lymphoma-2 (Bcl-2), T cell lymphoma 
breakpoint 1 (TCL-1), cell division control protein 42 
(CDC42), and phosphatidylinositol 3-kinase regulatory 
subunit a (PIK3R1) (21).
It has been previously reported that there is a relation 
between breast cancer and heat shock proteins (HSPs), 
which led to proliferation and resistance to apoptosis. 
HSPs are a group of extracellular proteins. It has been 
suggested that extracellular proteins play a critical role in 
the regulation of cancer cell migration and invasion, and 
because of their availability, they provide good targets for 
drug development (22). HSPs as molecular chaperones 
are increased in many types of cancer. The elevated levels 
of HSPs in tumor cells play a pivotal role in protection 
from apoptosis associated with malignancy in addition to 
apoptosis following therapy (23).
Here we downregulated the expression of miR-29a and 
assessed the expression of HSP-27, -40, -60, -70, and -90 on 
MCF-7 human breast cancer cell line. We hypothesize that 
miR-29a downregulation leads to a change in the expres-
sion of HSPs. Here we report an alternative way of inducing 
apoptosis in breast cancer, which could be used as a treat-
ment in combination with other routine procedures by tar-
geting miRNAs and HSPs. Also, we aimed to compare these 
outcomes in cells treated with Taxol, as commonly used che-




Human breast cancer cell line MCF-7 was obtained 
from the Stem Cell Technology Research Center (Iran) 
and cultured in the T25 flasks with appropriate culture 
media: Dulbecco’s modified Eagle’s medium  (Gibco 
BRL, Grand Island, NY, USA) supplemented with 10% 
fetal bovine serum (FBS; Gibco), 100 U/ml penicillin 
G, and 100 µg/ml streptomycin (Invitrogen, USA). The 
cells were maintained at 37°C in incubator with 5% CO2 
atmosphere. After 48 h, the adherent cells were trypsinized 
and removed from the flasks.
Knocking Down miR-29a in MCF-7 Cells 
by Reverse Transfection
miR-29a was knocked down according to reverse 
transfection method by specific anti-miR-29a small RNA 
against 3'p miR-29a sequence. Cells were harvested in 
logarithmic growth phase and adjusted in desired num-
ber by culture medium. Transfection reagents for each 
group were prepared and added into 96-well plates in 
triplicate, and cells were added and shaken to enforce 
transfection efficiency. Transfection of treated cells was 
monitored in groups treated by FITC-conjugated scram-
ble RNA under fluorescent microscopy and quantifica-
tion of miR-29a in scramble and anti-miR-29a-treated 
cells. Preprepared master mix of all required reagents 
for scramble (final concentration of 5 nM in 200 µl 
culture medium) (Santa Cruz, USA) and anti-miR-29a 
(Invitrogen, USA) in a final concentration of 50 nM 
were vortexed and incubated along with the transfec-
tion reagent (Invitrogen, USA) for 20 min at room tem-
perature. Then reagents were poured into the 96-well 
plate so that each of the three wells could be consid-
ered as a group, and finally, the cells (30 × 103 per well) 
were added (reverse transfection). Cell viability was 
assessed by trypan blue. Five groups were considered 
in this study. They were incubated for 24 h at 37°C and 
5% CO2. After that, Taxol, as an anticancer drug, was 
added to the fourth and fifth groups at the concentra-
tion of 10 ng/ml. The optimal concentration for Taxol in 
the cultured medium was determined after MTT [3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
assay (data not shown). All five groups were brought to 
a final volume of 200 µl and placed in the incubator.
Cell Viability Assay
Measurement of cell viability was conducted on 
treated and nontreated cells of each group by MTT assay. 
Briefly, 72 h posttransfection, culture medium was dis-
posed, and MTT solution (5 mg/ml) was added in equal 
volume and incubated in 5% CO2 and 37°C. Overlay 
medium was replaced by DMSO, and absorbance was 
measured in 590-nm wavelength. Viability index was cal-
culated by dividing the absorbance of each treated group 
to absorbance of nontreated group. All experiments were 
repeated three times.
RNA Extraction and cDNA Synthesis
Total RNA was extracted from seeded cells in different 
groups 72 h after transfection, using easy-BLUETM Total 
RNA Extraction kit (iNtRON Biotechnology, Korea) 
according to the manufacturer’s instructions. Then cDNA 
synthesis was performed for miR-29a (target gene) and 
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U6 snRNA (reference gene) by using specific primers 
(5¢-GTCGTATCCAGTGCAGGGTCCGAGGT ATTCG 
CACTGGATCAGACTAACCGAT-3¢ and 5¢-AAAATAT 
GGAACGCTTCACGAATTTG-3¢), respectively, in Stem 
loop RT-PCR with RevertAid H Minus First Strand cDNA 
Synthesis Kit according to the manufacturer’s protocol. 
(Thermo Scientific, USA).
cDNA synthesis for HSP27, HSP40, HSP6, HSP70, 
HSP90 (target genes), and hypoxanthine phosphoribosyl 
transferase (HPRT) (reference gene) was conducted using 
general primers (Random and Oligo dT primers) by Maxime 
RT premix cDNA synthesis (iNtRON Biotechnology). The 
thermocycler temperature program was 25°C for 5 s, 45°C 
for 1 min, and finally at 95°C for 5 s.
Quantitative Real-Time PCR
To evaluate gene expression levels, quantitative real-
time PCR performed on Corbett Rotor-gene 6000 instru-
ment (Corbett Life Sciences) by using SYBR green 
Master Mix. miR-29a and U6 snRNA genes were evalu-
ated with specific primers (miR-29; forward: 5¢-TGCGC 
TAGCACCATCTGAAA-3¢, reverse: 5¢-CAGTGCAGG 
GTCCGAGGAT-3¢ and U6 snRNA; forward: 5¢-CTCG 
CTTCGGCAGCACATATAC-3¢, reverse: 5¢-ACGCTTCA 
CGAATTTGCGTGTC-3¢) under the following condi-
tion: an initial step of 10 m at 95°C, followed by 95°C for 
15 s, 60°C for 40 s, and 72°C for 20 s, for 45 cycles, fol-
lowed by a melt cycle ramp from 55°C to 99°C. The PCR 
reactions were performed using cDNA samples (100 ng), 
10 µl of the Master mix SYBER Green 2X in RealMOD 
Green PCR kit (iNtRON Biotechnology), and 10 pmol of 
each primer. The sterile deionized water was used to attain 
a total volume of 20 µl. To evaluate variations in levels of 
HSP expression, we quantified their fold change expres-
sion by specific primers as follows: HSP27 forward: 
5¢-AGGATGGCGTGGTGGAGAT-3¢, reverse: 5¢-GAT 
GTAGCCATGCTCGTCCTG-3¢; HSP40 forward: 5¢-CC 
AGTCACCCACGACCTTC-3¢, reverse: 5¢-CCCTTCTTC 
ACTTCGATGGTCA-3¢; HSP60 forward: 5¢-TGCCAAT 
GCTCACCGTAAG-3¢, reverse: 5¢-ACTGCCACAACCT 
GAAGAC-3¢; HSP70 forward: 5¢-CCATCATCAGCG 
GACTGTAC-3¢, reverse: 5¢-CCATCATCAGCGGACT 
GTAC-3¢; HSP90 forward: 5¢-CGCTCCTGTCTTCTGG 
CTTC-3¢, reverse: 5¢-TGGTATCATCAGCAGTAGGG 
TC-3¢; hypoxanthine phosphoribosyl transferase (HPRT) 
forward: 5¢-GGACAGGACTGAACGTCTTGC-3¢, reverse: 
5¢-ATAGCCCCCCTTGAGCACAC-3¢.
All reactions were performed in triplicate and used 
the average values for relative quantification. We used 
the Pfaffl method to determine the relative quantity of 
gene expression. Brieﬂy, we normalized the cycle of the 
threshold (Ct) values of the target gene to the endogenous 
control gene and compared it with a calibrator (same gene 
in group without any treatment).
Statistical Analysis
The results were expressed as mean ± SD and analyzed 
using SPSS16 software. Difference between groups was 
evaluated by Kruskal Wallis, and comparison of stud-
ied groups for the expression of the desired genes was 
assessed by Mann/Whitney tests. A value of p £ 0.05 was 
considered as significance level.
Figure 1. Level of miR-29a expression in scramble and anti-miR-29a transfected cells.
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RESULTS
Knockdown of miR-29a
To reveal knockdown of miR-29a in studied cells, 
we quantified the expression of anti-miR-29a-treated 
cells compared to nontreated and scramble transfected 
cells by real-time PCR. Melting curve was considered 
to determine specific amplification of target genes. Our 
result showed fold change ratios of 0.193 and 0.043 for 
scramble and anti-miR-29a transfected cells, respectively, 
compared to nontreated group. These finding suggested 
efficient downregulation (p = 0.037) of miR-29a in anti-
miR-29a group (more than 99%) and 4.5 times more than 
the scramble-treated group (Fig. 1).
Effect of Knocking Down miR-29a on 
Cell Viability
The effects of inhibiting the miR-29a on viability of 
MCF-7 line breast cancer cells was evaluated through 
calculating the viability index in treated cells 72 h 
posttransfection of miR-29a antisense RNA. As demon-
strated in Figure 2, our results showed maximum reduc-
tion in viability has been seen in Taxol-treated cells 
(15%). Likewise, viability has diminished in MCF-7 cells 
treated by anti-miR-29a, about 10% compared to the con-
trol group with lower standard deviation than the Taxol 
group. Combination of Taxol and anti-miR-29a led to less 
reduction in viability index (about 6%).
Downregulation of miR-29a
Relative change in miR-29a expression was analyzed 
by the Pfaffl method. The cycle of threshold (Ct) values 
of the target gene (miR-29a) was normalized by reference 
gene (U6 snRNA) and compared with the nontreated 
group as calibrator. Our results showed 0.2- and 0.045-
fold changes in miR-29a expression, respectively, for the 
scramble and anti-miR-29a-treated cells. Therefore, anti-
miR treatment caused a significant reduction (77.5%) in 
miR-29a expression compared with the scramble-treated 
group (p £ 0.05).
Table 1. Fold Changes in HSP Gene Expression in Studied Groups
Category HSP27 HSP40 HSP60 HSP70 HSP90
Scramble 1.68 ± 0.11 78.1 ± 0.53 2.45 ± 0.5 1.7 ± 0.1 14.77 ± 6.11
Anti-mir-29a 0.486 ± 0.42 59.9 ± 9.85 5.07 ± 0.51 0.17 ± 0.03 0.75 ± 0.05
Anti-mir-29a + Taxol 0.656 ± 0.52 53.63 ± 8.16 4 ± 0.92 0.5 ± 0.00 0.393 ± 0.04
Taxol 0.087 ± 0.007 25.63 ± 2.29 0.2 ± 0.01 0.25 ± 0.05 0.133 ± 0.03
Figure 2. Cell viability index in MCF-7 line breast cancer cells after inhibiting the miR-29a. Data demonstrated as mean and standard 
deviation (SD) of ratio of obtained absorbance of formed formazan for treated groups to nontreated group.
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Quantification of Heat Shock Protein Genes 
in the Studied Groups
The target genes including HSP27, HSP40, HSP60, 
HSP70, and HSP90 were normalized by HPRT as a refer-
ence gene. For each gene, we had five groups: nontreated 
(calibrator), treatment by scramble, anti-miR-29a, anti-
miR-29a + Taxol and Taxol. Table 1 presents fold changes 
in the expression of HSPs in all the studied groups. Kruskal 
Wallis was used for analysis of the overall difference 
between the studied groups for the desired HSP genes.
miR-29a Inhibition Reduces HSP27 Expression. Our 
experiment showed that Taxol significantly reduced HSP27 
expression by about 95% in treated cells (p = 0.023), and 
anti-miR-29a addition also led to significant decrease in 
expression of HSP27 (more than 70%) compared to the 
scramble group (p < 0.05). As demonstrated in Figure 3, 
the combination of Taxol and anti-miR-29a lowered 
the anti-HSP27 expression effect of Taxol in the treated 
group. There was no significant difference between the 
anti-miR-29a alone-treated group and the group treated 
with Taxol + anti-miR-29a (about 60% reductions).
HSP40 Reduced in Anti-miR-29a-Treated Cells but 
not as Much as Taxol-Treated Cells. We observed about 
23% reduction in HSP40 expression in cells treated with 
anti-miR-29a in comparison with the scramble group 
(p = 0.05). As illustrated in Figure 4, the most declines in 
HSP27 were seen in the Taxol-treated group (more than 
67%). Decrease in HSP27 gene expression in combina-
tion of Taxol and anti-miR-29a-treated group was about 
33%, which did not show significant difference between 
the anti-miR-29a alone group (p = 0.513).
HSP60 Gene Upregulation in miR-29a Inhibited Cells. 
We found that inhibition of miR-29a leads to increased 
expression of HSP60 gene in MCF-7 cells by about 98% 
compared to the scramble group, while Taxol treatment 
alone reduced the expression to about 92%. As illustrated 
in Figure 5, contrary to Taxol that significantly decreased 
HSP60 (p = 0.046), the combination of anti-miR-29a and 
Taxol increased the HSP60, which is less than the anti-
miR-29a treatment alone. There is no significant differ-
ence between the anti-miR-29a-treated and combination 
groups (p = 0.127).
Inhibition of miR-29a Alone can Efficiently Decrease 
HSP70 Expression. Our results demonstrated that the 
scramble treatment courses a 1.7-fold increase in HSP70 
expression, while treatment with anti-miR-29a leads up 
to 90% decrease in HSP70 expression (p = 0.016). The 
other treatments with anti-miR-29a in combination with 
Taxol and Taxol alone, respectively, results in 70% and 
85% expression reduction compared to that of the scram-
ble group. These results showed an efficient decline of 
HSP70 in the anti-miR-29a-treated cells (p = 0.05). As 
presented in Figure 6, there is no apparent difference 
between HSP70 expression in the anti-miR-29a-treated 
Figure 3. Chart of HSP27 gene expression changes in the groups treated with scramble, anti-miR-29a, anti-miR-29a + Taxol, and 
Taxol compared with calibrator.
74 CHOGHAEI ET AL.
and the Taxol-treated groups, but a marked reduction in 
HSP70 expression was seen in the anti-miR-29a group in 
comparison to two other mentioned groups (p = 0.037).
Decreased Expression of HSP90 Gene in miR-29a 
Inhibited Cells. In the scramble treatment, nearly 14.8-
fold HSP90 expression was increased, while in the 
group treated with anti-miR-29a, HSP90 expression 
declined by 25% (Fig. 7). For the other studied groups, 
that is, treated with anti-miR-29a in combination with 
Taxol and Taxol alone, respectively, expression was 
reduced by about 60% and 97%. Thus, the treatment 
with anti-miR-29a could significantly reduce the expres-
sion of HSP90 by 95% lower than the scramble trans-
fected group (p < 0.05). This study showed that Taxol 
Figure 5. Chart of HSP60 gene expression changes in the groups treated with scramble, anti-miR-29a, anti-miR-29a + Taxol, and 
Taxol compared with calibrator.
Figure 4. Chart of HSP40 gene expression changes in the groups treated with scramble, anti-miR-29a, anti-miR-29a + Taxol, and 
Taxol compared with calibrator.
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Figure 6. Chart of HSP70 gene expression changes in the groups treated with scramble, anti-miR-29a, anti-miR-29a + Taxol, and 
Taxol compared with calibrator.
Figure 7. Chart of HSP90 gene expression changes in the groups treated with scramble, anti-miR-29a, anti-miR-29a + Taxol, and 
Taxol compared with calibrator.
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can significantly reduce HSP90 expression in compari-
son with anti-miR-29a (p < 0.05).
DISCUSSION
In recent studies, it has been reported that miR-29a is 
highly expressed in the MCF-7 cell line, and some stud-
ies revealed a high level of this small molecule in the 
sera of patients with breast cancer (17). The aim of this 
study was to evaluate whether the inhibition of miR-29a 
could efficiently induce the expression of HSP genes that 
are involved in apoptosis or proliferation of the MCF-7 
human adenocarcinoma breast cancer cell line.
miR-29a was downregulated by anti-miR-29a, and 
viability and the expression of HSP27, -40, -60, -70, and 
-90 were assessed in MCF-7 line breast cancer-treated 
cells. As presented in Table 1, although MCF-7 Taxol-
treated cells showed the lowest viability among the studied 
groups (15%), there are no significance differences in the 
miR-29a-inhibited group with 10% reduction in viable cells 
(p = 0.370), suggesting comparable consequence of miR-
29a downregulation on cancer cell apoptosis. Therefore, 
simultaneous use of Taxol and anti-miR-29a causes less 
reduction in viability, which is probably because of the 
negative interference of these two substances. These results 
agree with the expression pattern of HSPs in treated cells 
that have been previously described.
HSP27 is one of the most important HSPs in the growth 
of breast tumors owing to its prosurviving influence on 
breast cancer stem cells (CD44+) (24) and inducing angio-
genesis (25). Therefore, diminishing HSP27 can limit tumor 
growth and achieve a better response to chemotherapy 
(26). In this study, miR-29a downregulation significantly 
reduced HSP27 expression in anti-miR-treated MCF-7 
cells. Although Taxol was more effective in reducing 
HSP27 (Fig. 2), we believe this effect is nonspecific and is 
a temporary and limited effect of anti-miR-29a. Statistical 
analysis showed no significant difference between the Taxol 
and anti-miR-29a groups.
HSP40, as a chaperone, plays an important role in pro-
tein folding, transportation, and degradation in coordina-
tion with HSP70 (27). Regarding its relation to HSP70/
HSP90 complex, HSP40 can be involved in preventing 
cell death and the growth of cancer. Previous studies have 
shown a high level of JDP1, a member of the DnaJ/Hsp40 
family, in estrogen receptor-positive breast cancer cells 
(28). As demonstrated in Figure 3, inhibiting miR-29a 
expression reduced the HSP40 mRNA level in MCF-7 
cells, almost one third of the cells treated with Taxol. 
There was no significant effect in concomitant use of 
anti-miR-29a and Taxol compared to anti-miR-29a alone 
treatment, suggesting the modifying role of anti-miR-29a 
on Taxol-treated cells.
HSP60 is a mitochondrial chaperone and is present in 
cytosol, cell surface, and extracellular regions of normal 
and tumor cells (29). HSP60 interacts with a3b1 integrin 
and plays a role in adhesion of metastatic breast cancer 
cells to lymph nodes and osteoblasts. This interaction was 
inhibited by mizoribin, which was attached to HSP60.
HSP60 extracellular molecular interactions and intra-
cellular signaling play important roles in tumor cells. 
Through different mechanisms, such as the inhibition of 
intracellular antiapoptotic pathways and the activation 
of proapoptotic mechanisms, HSP60 shows its therapeu-
tic properties. The suppression of HSP60 through small 
interfering RNA (siRNA) caused apoptosis in colon and 
breast adenocarcinoma via mitochondrial dysfunction 
and impairment of P53–HSP60 complex. In our experi-
ment, we found that miR-29a inhibition led to a reduc-
tion in P53 (data not presented). According to these 
mechanisms, siRNA against HSP60 could be utilized as 
therapeutic agents in cancers such as colon and breast. In 
our experiments, we observed that anti-miR-29a caused 
an approximately 5.5-fold increase in the expression of 
HSP60. There are many reports regarding prosurvival and 
proapoptosis induction of HSP60. Some studies reported 
that accumulation of HSP60 can trigger apoptosis- 
independent mitochondrial release by activating caspase 
3 (30). Moreover, HSP60 can be the most common 
immunologic response to tumor cells through activation 
of T cells and releasing IFN-g and stimulating antigen- 
presenting cells (31–35). In contrast, Taxol leads to a sig-
nificant decrease in the level of HSP60 (approximately 
90%). The combination of Taxol and anti-miR-29a leads 
to a 4.8-fold increase in the level of HSP60. This finding 
demonstrated that the inhibition of miR-29a has a nega-
tive role in apoptosis augmentation in the breast cancer 
cell line through HSP60, while Taxol results in a decline 
in the level of HSP60. The incompatible effects of anti-
miR-29a and Taxol could be explained by the nonspecific 
mechanism of the Taxol function. While anti-miR-29a 
as a smart drug candidate targets specific molecules and, 
therefore, specific cellular pathways in tumor cells, Taxol 
interacts via a nonspecific mechanism involving a vari-
ety of targets in tumor and nontumor cells. The unwanted 
side effects and the unwanted effects of Taxol, among 
which is the reduction of HSP60, could be rationalized 
by this fact.
HSP70 plays an important role in tumor genesis 
through the apoptosis inhibition, induction of chemother-
apy resistance, and regulation of oncoprotein chemore-
sistance (29,36). Although the HSP70 expression level is 
low in normal cells, it has been elevated according to the 
poor prognosis and properties of malignancy. Thus, the 
inhibition of HSP70 attracts much attention as an antican-
cer treatment. Here we demonstrated that miR-29a inhi-
bition significantly decreased (about 90%) the expression 
of HSP70. Taxol, a common agent in cancer chemo-
therapy, reduced its expression around 85%. Using the 
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combination of anti-miR-29a + Taxol caused a decrease 
in the level of HSP70, which is less than that of each of 
the treatments (around 70%). According to these results, 
anti-miR-29a could be applied as a potent agent in the 
treatment of breast cancer by increasing drug sensitiza-
tion in cancer cells.
The previous reports revealed that HSP90 is one of 
the most important factors in the survival and growth of 
tumor cells. So the inhibition of this HSP could be poten-
tially useful in treatment. 17-N-Allylamino-17-demethoxy-
geldanamycin (17AAG), known as a HSP90 inhibitor, had 
antitumor influence on colon, prostate, and breast cancer. 
It acts as a tyrosine kinase inhibitor.
Due to its interaction with a variety of proteins that play 
key roles in breast neoplasia, such as estrogen receptors 
(ER), tumor-suppressor p53 protein, angiogenesis tran-
scription factor HIF-1a, antiapoptotic kinase Akt, Raf-1, 
mitogen-activated protein kinase, and a variety of recep-
tor tyrosine kinases of the erbB family, the pharmacologi-
cal inhibition of HSP90 could bring about new hope in 
the field of breast cancer treatment. Multiple oncogenic 
signaling pathways could be simultaneously suppressed 
using various inhibitors of HSP90, which in turn would 
reduce the possibility of molecular feedback loops and 
mutations leading to tumor resistance (15,27,34). Herein, 
we demonstrated that anti-miR-29a caused a reduction in 
the expression of HSP90, which is less than the Taxol 
effect. When anti-miR-29a was used with Taxol, we 
observed less reduction. One of the explanations for this 
finding can be that anti-miR-29a and Taxol were added to 
the test at different time points. Anti-miR-29a was added 
to the test group because anti-miR-29a was demolished 
by endonucleases in a short time. But Taxol was added 
24 h following the addition of anti-miR-29a. It is impor-
tant to mention that, although Taxol and anti-miR-29a 
separately reduced the HSP90 expression, they had no 
synergistic effect according to results.
CONCLUSIONS
Taxol, known as a chemotherapeutic agent with a 
long life span and high permeability, is infiltrated all 
over the body through the blood and had side effects on 
nontumor cells. Due to the adverse influences of this 
drug on normal cells, its application has been limited. 
Unlike Taxol, miR-29a inhibitors could be potentially 
utilized as efficient smart drugs, which directly influ-
ence breast-derived tumor cells that express miR-29a at 
a high level. Also, downregulating the miR-29a could 
potentially target susceptible cancer cells with a lower 
dose of chemotherapy. However, to reveal the in vivo 
therapeutic effect of miR-29a inhibition strategy, it 
should be chemically modified to improve its shelf life. 
However, we believe that more investigation is required 
at the cell and animal levels to verify these claims.
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